SciELO - Scientific Electronic Library Online

 
vol.46 issue1Stroke-like as the first debut late onset MELASDiagnostic utility of ancillary tests in dementia workups, systematic review: Part 1: Neuroimaging author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista chilena de neuro-psiquiatría

On-line version ISSN 0717-9227

Abstract

GAVIRIA M.D., Silvia Lucía. Treatment of bipolar disorder during pregnancy. Rev. chil. neuro-psiquiatr. [online]. 2008, vol.46, n.1, pp.43-54. ISSN 0717-9227.  http://dx.doi.org/10.4067/S0717-92272008000100006.

A number offactors must be evaluated in order to determine the safety ofany medication that is being considered for use during pregnancy All psychotropic medications diffuse readily across the placenta. No psychotropic medication has been approved by the Food and Drug Administration (FDA) for use during the pregnancy and pregnant women have traditionally been excludedfrom pharmacologic research. Numerous studies have shown a high relapse rate in psychiatrkpatient during the pregnancy whose medications were discontinued. When deciding whether or not to treat a psychiatrk patient during the pregnancy the guiding principie is to weigh the risks of fetal exposure to a psychotropic medication against the risks to both the mother and fetus of not treating a psychiatrk illness. Patients with bipolar disorder are at significant risk of relapse ifuntreated, particularly following abrupt discontinuation oflithium. Untreated bipolar illness with recurrence of mania may result in progression of the disorder. Another risk is disease chronkity and treatment resistance

Keywords : Bipolar disorder; pregnancy psychotropic medications.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License